Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-1334-2022

Drug recall · August 17, 2022

Azacitidine for Injection 100mg/vial Lyophilized Powder recall

Why: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56

Lots / codes

Lot: FE22001A, Exp 01/2024

Quantity
4162 cartons
Company
Teva Pharmaceuticals USA Inc, Parsippany, NJ
Distribution
Distributed in Ohio
Initiated
July 22, 2022 · Voluntary: Firm initiated
Classified
August 11, 2022
Reported
August 17, 2022
Ended
April 12, 2023
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Azacitidine

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.